Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Princeton, NJ
SEC filing record 1 source field available
Fiscal year end
31 December
AMICUS THERAPEUTICS, INC. has filed 2,174 SEC EDGAR filings since 25 Jul 2002

SEC filing history

Showing 851-875 of 1,000 matching filings.

Per page
25
Current page
35
4

FORM 4 SUBMISSION

Filing date
15 Apr 2019
Reporting date
11 Apr 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Apr 2019
Reporting date
11 Apr 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Apr 2019
Reporting date
11 Apr 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Apr 2019
Reporting date
11 Apr 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Apr 2019
Reporting date
11 Apr 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
08 Apr 2019
Reporting date
05 Apr 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
03 Apr 2019
Reporting date
01 Apr 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
28 Mar 2019
Reporting date
26 Mar 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33497

8-K

Filing date
20 Mar 2019
Reporting date
20 Mar 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
CT ORDER File 001-33497

CT ORDER filing

Filing date
18 Mar 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33497

8-K

Filing date
13 Mar 2019
Reporting date
12 Mar 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
05 Mar 2019
Reporting date
01 Mar 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33497

8-K

Filing date
28 Feb 2019
Reporting date
28 Feb 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33497

8-K

Filing date
28 Feb 2019
Reporting date
28 Feb 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
27 Feb 2019
Reporting date
25 Feb 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33497

8-K

Filing date
26 Feb 2019
Reporting date
26 Feb 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-33497

8-K

Filing date
25 Feb 2019
Reporting date
25 Feb 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
19 Feb 2019
Reporting date
12 Feb 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-83043

AMENDMENT NO. 5 TO SCHEDULE 13G

Filing date
14 Feb 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-83043

SCHEDULE 13G/A

Filing date
14 Feb 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-83043

SC 13G/A filing

Filing date
14 Feb 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-83043

AMICUS THERAPEUTICS, INC.

Filing date
14 Feb 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-83043

SC 13G/A filing

Filing date
13 Feb 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-83043

JANUS HENDERSON GROUP PLC OWNS 5.9% OF AMICUS THERAPEUTICS

Filing date
12 Feb 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .